+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Mesenchymal Stem Cells - Advances and Applications, 2021

  • ID: 5240709
  • Report
  • April 2021
  • Region: Global
  • 276 Pages
  • BioInformant
1 of 4

FEATURED COMPANIES

  • 101 Bio
  • Avalon GloboCare Corp.
  • Ciloa
  • ExoCoBio, Co., Ltd.
  • Medipost, Co., Ltd.
  • Regenexx
  • MORE

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cell types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogeneic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth.

Naturally, a broad range of research products has been developed around MSCs and their differentiated cell types. Growing attention is also being given to manufacturing technologies to support the commercial-scale production of MSCs. MSCs are well-suited for use in the exponential growth field of 3D printing, because of their capacity to form structural tissues. Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes because these extracellular “packages” represent a novel strategy for accessing the therapeutic effects of stem cells without the risks of administering whole cells to patients. Finally, gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application.

As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well as over 1,100 MSC clinical trials underway worldwide. Current “hotspots” for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. Population aging and an increasing prevalence of chronic disease are also driving interest in MSC-based therapies. Furthermore, Google Trend data reveals that MSC searches are more than twice as common as the next most common stem cell type. The demand for both MSCs and MSC-based research products have surged in recent years.

Today in 2021, nearly one-hundred different market competitors are developing various types of MSC-related products/services, therapies, and manufacturing technologies. Within this ever-changing landscape, having a thorough understanding of the competition and their relative strengths and weaknesses is essential. Therefore, this global strategic report details the activities of 98 leading MSC companies. It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.

With the competitive nature of this global market, you do not have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

The main objectives of this report are to provide the reader with the following details:

  • Market size determination for the global MSC market, segmented by geography and business segment
  • Five-year forecasts for the global MSC market
  • Details of the product candidates being developed by MSC companies
  • MSC market trends, opportunities, risks, and competitive dynamics
  • Major diseases addressed by MSCs in the ongoing clinical trials
  • Cost of manufacturing autologous and allogeneic MSCs
  • Consumption of MSCs for academic research, clinical trials, product development, and exosome production
  • Trend rate data for MSC scientific publications
  • Rates, quantities, geographic locations, and types of MSC clinical trials
  • Types and sources of MSC industry funding
  • Recent business developments related to MSCs
  • MSC-based products with marketing approval and the companies commercializing them
  • Currently marketed MSC-based bone matrices
  • Pricing comparison of MSC-based products with marketing approval
  • Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production, and cosmeceuticals
  • Company profiles for 98 MSC market competitors, including their proprietary technologies and products/services under development  

To analyze the rapidly evolving stem cell sector, the publisher conducts ongoing interviews with prominent executives from across the field. To assess MSC market dynamics, the research team interviewed representatives from Cynata Therapeutics (the first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (worlds leading provider of MSC therapies for orthopedic applications), and numerous others. As the first and only market research firm to specialize in the stem cell industry, the publisher is your trusted leader in the stem cell industry data.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 101 Bio
  • Avalon GloboCare Corp.
  • Ciloa
  • ExoCoBio, Co., Ltd.
  • Medipost, Co., Ltd.
  • Regenexx
  • MORE

1. REPORT OVERVIEW
1.1 Statement of the Report
1.2 Target Demographic
1.3 Report Sources
1.4 Purpose of the Report
1.4.1 To Survey Recent MSC Advancements
1.4.2 To Provide a “Snapshot” of Global MSC Market
1.4.3 To Assess Opportunities for Commercialization
1.4.4 To Identify Major Market Players and Assess the Competitive Environment
1.4.5 To Identify Existing and Emerging Trends
1.4.6 To Identify Critical Opportunities and Threats within the MSC Market
1.5 Executive Summary
1.6 Introduction

2. MESECHYMAL STEM CELLS (MSCS): AN OVERVIEW
2.1 The Impact of MSCs on Regenerative Medicine
2.2 Timeline of MSC Nomenclature
2.3 Sources of MSCs
2.3.1 Bone Marrow-Derived MSCs (BM-MSCs)
2.3.2 Adipose-Derived MSCs (AD-MSCs)
2.3.3 Umbilical Cord-Derived MSCs (UC-MSCs)
2.4 Cell Surface Markers in MSCs
2.5 In Vitro Differentiation Potentials of MSCs
2.6 Soluble Factors Secreted by MSCs

3. MANUFACTURE OF MESENCHYMAL STEM CELLS
3.1 Methods of Isolation of MSCs
3.2 From Conventional Cultures to Bioreactors
3.2.1 Monolayer Culture Systems
3.2.2 Bioreactor-Based Cell Expansion
3.2.3 Stirred Tank Bioreactor
3.2.4 Rocking Bioreactor
3.2.5 Hollow Fiber Bioreactors
3.2.6 Fixed-Bed Bioreactors
3.3 Main Features of Commercial Bioreactors
3.4 Microcarriers used for the Expansion of MSCs
3.5 Downstream Processing of MSCs
3.5.1 Cell Detachment and Separation
3.5.2 Cell Washing and Concentration
3.5.3 Safety and Potency Assays
3.5.4 Surface Markers for Identification during MSC Manufacture

4. COMPARISON OF AUTOLOGOUS AND ALLOGENEIC MSC MANUFACTURE
4.1 Manufacturing Cost Compared
4.1.1 Cost Differential
4.1.2 Cost of Donor Screening and Testing
4.1.3 Cost for Release Testing
4.2 Comparison of the Two Business Models
4.2.1 Risk of Immune Reaction
4.2.2 Risk of Cross Contamination
4.2.3 Commercially Attractive Option
4.3 Cost Breakdown in MSC Manufacturing
4.4 Opportunities for Cost Reduction
4.5 Partial Automation vs. Full Automation
4.5.1 Partial Automation: The Most Attractive Option

5. SMALL SCALE PROCESSING OF MSCS
5.1 Model Design
5.2 Culture Media

6. LARGE-SCALE EXPANSION OF MSCS
6.1 The Four Common Bioprocessing Strategies for Large-Scale Expansion
6.2 Commonly Used Sources of MSCs for Large-Scale Expansion
6.3 The Commonly Used Culture Medium for the Large-Scale Expansion of MSCs
6.3.1 Expansion Ratio Achieved with Different Culture Media
6.4 Comparison between Large-Scale Bioprocessing Strategies
6.5 Contract Manufacturing for Cell Therapies
6.5.1 Contract Manufacturing Organizations (CMOs)
6.5.2 Contract Development and Manufacturing Organizations (CDMOs)
6.5.2.1 Major Services Offered by CMOs
6.5.2.2 Regional Distribution of CMOs
6.6 Global Cell Therapy Manufacturing Capacity
6.6.1 Major Cell Therapy CMOs/CDMOs in the U.S
6.6.2 Major CMOs/CDMOs for Cell Therapy Manufacturing in Europe

7. ESTIMATED CONSUMPTION OF MSCS IN THE INDUSTRY
7.1 Consumption of MSCs in Academic and Preclinical Settings
7.2 MSC Consumption in Clinical Settings
7.3 Consumption of MSCs by Target Indications in Clinical Trials
7.4 Future Consumption through 2030
7.4.1 Consumption for MSC Therapeutics
7.4.2 Consumption for Engineered Tissues and Organs
7.4.3 MSC Consumption by MSC-Derived Products
7.4.4 MSC Consumption in Emerging Industries
7.5 Cost of MSCs per Patient used in Clinical Trials by Indication

8. PUBLISHED SCIENTIFIC PAPERS ON MSCS
8.1 Number of Papers on MSCs & iPSCs Compared
8.2 Number of Papers on MSCs by Source
8.3 Number of Papers Published on Clinical Trials Involving MSCs
8.3.1 Number of Papers on Clinical Trials using MSCs for Specific Diseases

9. CLINICAL TRIALS OF MSCS, MSC-BASED COVID-19, MSC-EXOSOMES
9.1 Analysis of Data from ClinicalTrials.gov
9.2 Sources of MSCs for Clinical Trials
9.3 Autologous vs. Allogeneic MSCs
9.4 Regional Distribution of MSC-Based Clinical Trials
9.4.1 Major Countries Involved in MSC-Based Clinical Trials
9.5 Types of Funding for MSC-Based Clinical Trials
9.6 Types of MSC-Based Clinical Trials
9.7 MSC-Based Clinical Trials by Phase of Development
9.8 Clinical Trials Involving MSCs for the Treatment of COVID-19
9.8.1 MSC-Based COVID-19 Clinical Trials by Geography
9.9 Clinical Trials Involving MSC-Derived Exosomes
9.10 NIH Funding for MSC Research
9.11 CIRM’s Funding for MSC Projects
9.11.1 CIRM Funding for MSC-Based Clinical Trials

10. CURRENT SUB-OPTIMAL CLINICAL OUTCOMES & SOLUTIONS
10.1 To Overcome Challenges Arising from MSC Manufacture
10.1.1 Heterogeneity in the MSC Product
10.2 Cryopreservation and Culture Rescue
10.2.1 Bioengineering Solutions to Boost MSC Function
10.2.2 Engineering MSCs to Carry Anti-Cancer “Trogan Horses”
10.3 Overcoming Clinical Challenges Related to Infusion
10.3.1 Local Administration
10.3.2 Insufficient Retention and Survival
10.3.3 Strategies to Improve Local Administration
10.4 To Overcome Clinical Challenges from the Host

11. MODIFICATION OF MSCS
11.1 Genetic Modification
11.1.1 Gene Modification to Improve Migration
11.1.2 Gene Modification to Improve Adhesion
11.1.3 Genetic Modification to Improve Survival
11.1.4 Genetic Modification to Reduce Premature Senescence
11.2 Preconditioning Modifications
11.2.1 Preconditioning to Improve Migration
11.2.2 Preconditioning to Improve Adhesion
11.2.3 Preconditioning to Improve Survival
11.2.4 Preconditioning to Reduce Senescence
11.3 Therapeutic Application of Modified MSCs
11.3.1 Modified MSCs for Neurological Conditions
11.3.2 Modified MSCs for Cardiovascular Diseases
11.3.3 Modified MSCs for Lung Injury
11.3.4 Modified MSCs for Diabetes

12. MAJOR DISEASES ADDRESSED BY MSCS IN CLINICAL TRIALS
12.1 Clinical Trials using MSCs for Autoimmune Diseases
12.2 Clinical Trials using MSCs for Cardiovascular Diseases
12.3 Clinical Trials using MSCs for Neurodegenerative Diseases
12.4 Clinical Trials using MSCs for Bone and Cartilage Diseases

13. PRESENT STATUS OF MESENCHYMAL STEM CELL INDUSTRY
13.1 Sources of MSCs for Research and Clinical Applications
13.2 Allogeneic Products Gaining Traction
13.3 MSC-Based Products with Marketing Approval
13.3.1 Alofisel
13.3.2 Stemirac
13.3.3 Stempeucel
13.3.4 Temcell HS
13.3.5 Neuronata-R
13.3.6 Prochymal (Remestemcel-L)
13.3.7 Cupistem
13.3.8 Cartistem
13.3.9 Cellgram-AMI
13.3.10 Queencell
13.4 Currently Marketed MSC-Based Bone Matrices
13.4.1 Osteocel
13.4.2 AlloStem
13.4.3 Cellentra VCBM
13.4.4 HiQCell
13.4.5 Trinity ELITE
13.4.6 Map3
13.4.7 Trinity Evolution
13.4.8 Carticel
13.4.9 Chondron
13.4.10 DeNovo NT
13.4.11 Chondrocelect
13.4.12 Ossron
13.4.13 JACC
13.4.14 MACI
13.4.15 Ortho-ACI
13.4.16 Spherox
13.4.17 Ossgrow
13.4.18 Cartigrow
13.4.19 ViviGen
13.4.20 Bio4
13.4.21 Cartiform
13.5 From Whole Cell MSC Therapy to MSC-Derived Exosome Therapy
13.5.1 Advantages of MSC-Derived Exosomes
13.5.2 Contents of MSC-Derived Exosomes
13.5.3 Exosomes as Diagnostics
13.5.4 Exosomes as Drug Delivery Vectors
13.6 MSC-Based Therapy for COVID-19
13.7 MSC-Based Clean Meat Production
13.8 Stem Cell-Based Cosmetics
13.8.1 Marketed Stem Cell-Based Cosmetic Products

14. MARKET ANALYSIS
14.1 Price Tags for MSC-Based Cell Therapy (CT) Treatment
14.2 Price Tags for MSC-Based Matrices
14.3 Market Size of MSC-Based Therapies
14.4 Global Market for MSC-based Therapeutics
14.5 Global Demand for Mesenchymal Stem Cells (MSCs)
14.5.1 MSCs Required for Academic and Preclinical Research
14.5.2 Required MSCs for Clinical Trials
14.5.3 MSCs Required for Developing MSC-Based Therapeutics
14.5.4 MSCs Required for Developing MSC-Derived Products
14.5.5 MSCs Required for Emerging Industries
14.5.6 Global Market Size for Mesenchymal Stem Cells
14.6 Market Share of MSC-Based Business Segments

15. COMPANY PROFILES
15.1 101 Bio
15.1.1 Exosome Services
15.2 Adipomics, Inc.
15.3 Aegle Therapeutics
15.3.1 Aegle’s Platform Technology
15.3.1.1 Epidermolysis Bullosa
15.4 Aethlon Medical, Inc.
15.4.1 Hemopurifier in Cancer
15.5 AgeX Therapeutics, Inc.
15.5.1 PureStem Technology
15.5.2 Induced Tissue Regeneration (iTR)
15.5.3 UniverCyte
15.6 Alexerion Biotech Corp.
15.6.1 Drug Development
15.7 AlloSource, Inc.
15.7.1 Products
15.7.1.1 AlloStem
15.8 American CryoStem Corporation
15.8.1 Services
15.8.1.1 ATGRAFT Fat Storage
15.8.1.2 Adult Stem Cell Program
15.8.2 Products
15.8.2.1 CELECT Tissue Harvesting System
15.8.2.2 ATCELL-AD-MSCs
15.8.2.3 ACSelerateMAX Growth Medium
15.9 American Type Culture Collection (ATCC)
15.9.1 Stem Cell Products
15.10 AMS Biotechnology, Ltd. (AMSBIO)
15.10.1 Products
15.11 Anemocyte S.r.l
15.11.1 Total GMP Capacity
15.11.2 Product Types
15.11.3 Manufacturing Services
15.12 Anjarium Biosciences
15.12.1 Anjarium’s Hybridosome Platform
15.13 Anterogen, Co., Ltd.
15.13.1 Products
15.13.1.1 Cupistem Injection
15.13.1.2 Queencell Injection
15.14 Apceth Biopharma GmbH
15.14.1 Global Services
15.14.2 Assay Development Services
15.15 Aruna Bio
15.15.1 AB126
15.16 Athersys, Inc.
15.16.1 MultiStem
15.17 Avalon GloboCare Corp.
15.17.1 Avalon’s Core Platforms
15.18 Axol Bioscience, Ltd.
15.18.1 Products
15.19 Azymus Therapeutics
15.19.1 AZ Platform
15.20 BioCat GmbH
15.20.1 Exosome Purification Kits
15.21 BioFluidica
15.21.1 Technology Platform
15.22 Bio-Techne
15.22.1 Total GMP Capacity
15.22.2 Prtoduct Types
15.23 BioVision, Inc.
15.24 Baylx, Inc.
15.24.1 Product Candidates
15.25 BrainStorm Cell Therapeutics
15.25.1 MSC-NTF Cells
15.26 Capricor Therapeutics
15.26.1 Exosome Program
15.27 Catalent Pharma Solutions
15.27.1 Cell Therapy Expertise
15.28 CCRM
15.28.1 Total GMP Capacity
15.28.2 Product Types
15.28.3 Manufacturing Services
15.29 CellResearch Corporation, Pte Ltd.
15.29.1 Umbilical Cord Lining Stem Cells
15.30 Celltex Therapeutics Corporation
15.30.1 Therapy Services
15.31 Ciloa
15.31.1 Exosome Customization Technology
15.32 Codiak Biosciences
15.32.1 engEx Platform
15.32.2 exoASO-STAT6
15.32.3 exoIL-12
15.33 Corestem, Inc.
15.33.1 Neuronata-R
15.34 CO-DON AG
15.34.1 M-ACT
15.35 Cognate BioServices, Inc.
15.35.1 Total GMP Capacity
15.35.2 Product Types
15.36 Creative Bioarray
15.37 Creative Biolabs
15.37.1 Products
15.37.2 Services
15.38 Cynata Therapeutics, Ltd.
15.38.1 Cymerus Platform
15.38.2 GvHD
15.38.3 Critical Limb Ischemia
15.38.4 Asthma
15.38.5 Heart Attack
15.38.6 Diabetic Wounds
15.38.7 Coronary Artery Disease (CAD)
15.38.8 Acute Respiratory Distress Syndrome (ARDS)
15.38.9 Sepsis
15.38.10 Osteoarthritis
15.39 DePuy Synthes
15.39.1 ViviGen
15.40 Direct Biologics
15.40.1 ExoFlo
15.41 EVerZom
15.41.1 Services
15.42 Evox Therapeutics, Ltd.
15.42.1 Protein Therapeutics – REPLACE
15.42.2 RNA Therapeutics – CORRECT
15.43 Exerkine Corp.
15.43.1 Clinical Development
15.43.1.1 Genetic Diseases
15.43.1.2 Aging-Associated Diseases
15.44 ExoCan Healthcare Technologies, Pvt. Ltd.
15.44.1 Technology
15.44.1.1 ExoEnrich Exosome Isolation Kit
15.44.1.2 ExoEngineering
15.45 ExoCoBio, Co., Ltd.
15.45.1 Products
15.46 Exogenus Therapeutics
15.47 EXoPERT
15.47.1 EXo-i
15.48 Exopharm
15.48.1 LEAP Technology
15.48.2 Cevaris & Plexaris
15.49 Exosome Diagnostics, Inc.
15.49.1 ExoDx Prostate Test
15.50 ExosomePlus
15.51 Exosome Sciences
15.51.1 TauSome Biomarker
15.52 Exosomics S.p.A
15.52.1 ExoRef
15.52.2 SeleCTEV Enrichment Kits
15.52.3 SoRTEV Enrichment Kit
15.53 Fraunhofer Institute for Cell Therapy and Immunology
15.53.1 Total GMP Capacity
15.53.2 Product Types
15.53.3 Manufacturing Services
15.54 HansaBioMed Life Sciences, Ltd.
15.54.1 Products
15.55 Hope Biosciences, LLC
15.55.1 Hope’s Cell Culture Process
15.56 Japan Tissue Engineering, Co., Ltd.
15.56.1 JACC
15.57 JCR Pharmaceuticals, Co., Ltd.
15.57.1 TEMCELL HS Inj.
15.58 Kimera Labs, Inc.
15.59 Lonza Group Ltd.
15.59.1 Total GMP Capacity
15.59.2 Product Types
15.59.3 Manufacturing Services
15.60 Mantra Bio
15.60.1 Partnering
15.61 Medipost, Co., Ltd.
15.61.1 Cartistem
15.62 MDimune
15.62.1 BioDrone Technology
15.63 NanoSomix, Inc.
15.63.1 Technology
15.64 NanoView Biosciences
15.64.1 Products
15.64.1.1 ExoView R
15.64.1.2 ExoView Tetraspanin Kits
15.65 NeurExo Sciences
15.66 Nipro Corporation
15.66.1 Stemirac
15.67 Novus Biologicals, LLC
15.67.1 Exosomes Research Tools
15.68 NuVasive, Inc.
15.68.1 Osteocel Family
15.69 OmniSpirant Limited
15.69.1 Technology
15.70 Orthocell, Ltd.
15.70.1 Ortho-ATI
15.70.2 CelGro
15.71 Orthofix Medical, Inc.
15.71.1 Trinity ELITE
15.71.2 Trinity EVOLUTION
15.72 Osiris Therapeutics, Inc.
15.72.1 Cartiform
15.72.2 Bio4
15.73 Pharmicell, Co., Ltd.
15.73.1 Cellgram-AMI
15.73.2 Stem Cell Culture Media Cosmetics
15.74 Pluristem Therapeutics, Inc.
15.74.1 Products
15.74.2 PLX-PAD
15.74.3 PLX-R18
15.74.4 PLX-Immune
15.74.5 Partnerships and Collaborations
15.74.5.1 Collaboration with NASA
15.74.5.2 Collaboration with NIAID
15.74.5.3 Collaboration with U.S. Department of Defence (DOD)
15.74.5.4 License Agreement with Chart Industries, Inc.
15.74.5.5 Collaboration with Thermo Fisher Scientific
15.74.5.6 Partnership with Cha Biotech
15.75 Regeneus, Ltd.
15.75.1 HiQCell
15.76 Regrow Biosciences, Pvt., Ltd.
15.76.1 Ossgrow
15.76.2 Cartigrow
15.77 ReNeuron
15.77.1 Exosome Platform
15.78 RoosterBio
15.78.1 Products
15.78.2 Services
15.79 RoslinCT
15.79.1 Total GMP Capacity
15.79.2 Product Types
15.79.3 Manufacturing Services
15.80 RTI Surgical, Inc.
15.80.1 Map3 Allograft Chips
15.81 Sentien Biotechnologies, Inc.
15.81.1 SBI-101
15.81.2 Pipeline
15.82 STEMCELL Technologies, Inc.
15.82.1 Products
15.83 Stemedica Cell Technologies, Inc.
15.83.1 BioSmart Technology
15.83.2 Pipeline
15.84 Stemmatters Biotechnologia e Medicina Regenerative SA
15.85 Stempeutics Research, Pvt., Ltd.
15.85.1 Stempeucel
15.85.2 Stempeutron
15.85.3 Stempeucare (Cutisera)
15.86 System Biosciences, LLC
15.86.1 Products
15.86.2 Services
15.87 Takeda Pharmaceuticals U.S.A., Inc.
15.87.1 Alofisel
15.88 Tempo Bioscience
15.88.1 Products
15.88.1.1 Human Cell Models
15.88.1.2 Services & Alliances
15.89 Tavec Pharma
15.89.1 Technology
15.90 United Therapeutics Corp.
15.90.1 Unexisome
15.91 Vericel Corporation
15.91.1 MACI
15.91.2 Carticel
15.92 Versatope Therapeutics
15.92.1 VT-105
15.93 Vesigen Therapeutics, Inc.
15.93.1 Technology
15.94 Waisman Biomanufacturing
15.94.1 Total GMP Capacity
15.94.2 Product Types
15.94.3 Manufacturing Services
15.95 WuXi Advanced Therapies
15.95.1 Total GMP Capacity
15.95.2 Product Types
15.96 XOStem, Inc.
15.97 Zen-Bio, Inc.
15.97.1 Products
15.97.1.1 Human Exosomes
15.97.2 Contract Services
15.98 Zimmer Biomet
15.98.1 Cellentra

Index of Figures
Figure 3.1: Monolayer Culture Systems
Figure 3.2: Stirred Tank Bioreactor
Figure 3.3: Rocking Bioreactor
Figure 3.4: Hollow Fiber Bioreactors
Figure 3.5: Fixed-Bed Bioreactors
Figure 3.6: Single-Use Harvestainer for Small Scale Application
Figure 3.7: Single-Use Harvestainer for Large Scale Application
Figure 4.1: CoG in MSC Manufacturing
Figure 4.2: Impact of Head Count on Overall CoG per Batch
Figure 4.3: CoG Breakdown in Partially-Automated MSC Manufacturing
Figure 4.4: Cost Breakdown in Fully Automated MSC Manufacturing
Figure 4.5: Higher Throughput in Partially Automated Facilities
Figure 5.1: Diagrammatic Representation of SelecT Automated Platform by Sartorius
Figure 5.2: Model of a Clean Room in a Small-Scale Manufacturing Facility
Figure 6.1: The Four Common Bioprocessing Strategies
Figure 6.2: Large-Scale Expansion of MSCs by Source
Figure 6.3: Commonly used Culture Media in the Large-Scale Expansion of MSCs
Figure 6.4: Major Services Offered by CMOs
Figure 6.5: Regional Distribution of CMOs
Figure 7.1: Share of Published Papers by Type
Figure 7.2: Consumption of MSCs in Academic and Preclinical Settings
Figure 7.3: MSC Consumption in Clinical Settings
Figure 7.4: Consumption of MSCs by Target Indications in Clinical Trials
Figure 8.1: Number of Published Papers on MSCs between 2010 and 2020
Figure 8.2: Number of Published Papers for MSCs and iPSCs Compared, 2010-2020
Figure 8.3: Number of Papers on MSCs by Source
Figure 8.4: Number of Papers on Clinical Trials Involving MSCs
Figure 8.5: Percent Share of Specific Diseases in Clinical Trials
Figure 9.1: Distribution of Clinical Trials involving MSCs across the World, 2020
Figure 9.2: Clinical Trials Involving MSCs by Source
Figure 9.3: Clinical Trials Involving Autologous and Allogeneic MSCs
Figure 9.4: Distribution of MSC-Based Clinical Trials by Geography, 2020
Figure 9.5: Type of Funding for MSC-Based Clinical Trials
Figure 9.6: The Three Types of Ongoing MSC-Based Clinical Trials, 2020
Figure 9.7: MSC-Based Clinical Trials by Phase of Development, 2020
Figure 9.8: MSC-Based COVID-19 Clinical Trials by Geography
Figure 10.1: Bioengineering Solutions to Boost the Function of MSC
Figure 10.2: Bioengineering Solutions for Improving Administration of MSCs
Figure 10.3: Solutions to Overcome Host Factors
Figure 11.1: Four Focal Points of Enhancement of MSC’s Properties during Modification
Figure 11.2: The Cycle of Naïve MSCs to Modified MSCs for Clinical Application
Figure 12.1: Major Diseases Addressed by MSCs in Clinical Trials
Figure 12.2: Percent Share of Autoimmune Diseases in Clinical Trials using MSCs
Figure 12.3: Percent Share of MSC by Source in Trials for Cardiovascular Diseases
Figure 12.4: Percent Shares of Neurodenerative Diseases in Clinical Trials using MSCs
Figure 12.5: Percent Share of MSC by Source in Trials for Bone & Cartilage Diseases
Figure 14.1: Percent Share of Marketed CT, GT and TE Products
Figure 14.2: Percent Share of CT Products by Indication
Figure 14.3: Market for MSC-Based Cell Therapy Products by Geography, 2020-2027
Figure 14.4: Global Market for Mesenchymal Stem Cells by Geography, 2020-2027
Figure 14.5: Market Share of MSCc by Business Segments

Index of Tables
Table 2.1: Timeline of MSC Nomeclature
Table 2.2: Sources of MSCs
Table 2.3: Advantages and Disadvantages of BM-MSCs
Table 2.4: Advantages and Disadvantages of AD-MSCs
Table 2.5: Advantages and Disadvantages of UC-MSCs
Table 2.6: Positive and Negative Markers for MSCs Derived from Different Sources
Table 2.7: In Vitro Differentiation Potentials of MSCs
Table 2.8: Soluble Factors Secreted by MSCs
Table 3.1: Initial Story of MSCs: A Snapshot
Table 3.2: Methods of Isolation of MSCs and Corresponding Culture Media
Table 3.3: A Snapshot of Commercially Available Culture Systems
Table 3.4: Main Features of Commercially Available Bioreactors
Table 3.5: Microcarriers used for the Expansion of MSCs
Table 3.6: Basic Assays for MSCs
Table 3.7: Cell Surface Markers on MSCs and Fibroblasts
Table 4.1: Cost of Manufacturing Allogeneic MSCs
Table 4.2: Cost of Manufacturing Autologous MSCs
Table 4.3: Comparison of Allogeneic and Autologous Therapies
Table 4.4: Cost of Goods (CoG) in MSC Manufacturing
Table 4.5: CoG Breakdown in Partially-Automated MSC Manufacturing
Table 4.6: Cost Breakdown in Fully Automated MSC Manufacturing
Table 4.7: Higher Throughput in Partially Automated Facilities
Table 5.1: Key Process and Cost Assumptions
Table 5.2: Quality Control Panel with Cost Assessments
Table 5.3: Additional Supporting Labor Cost Assumptions
Table 5.4: Additional Supporting Facility and Process Assumptions
Table 6.1: Large-Scale Expansion of MSCs by Method, Cell Source and Media
Table 6.2: Expansion Ratio Achieved with Different Culture Media
Table 6.3: Comparison between Large-Scale Bioprocessing Strategies
Table 6.4: Regional Distribution of CMOs
Table 6.5: Global Cell Therapy Manufacturing Capacity
Table 6.6: Major CDMOs and CMOs in North America
Table 6.7: Major CDMOs and CMOs in Europe
Table 7.1: Cost of MSCs per Patient in Clinical Trials by Indication
Table 8.1: Number of Published Papers on MSCs between 2010 and 2020
Table 8.2: Number of Papers on MSCs & iPSCs Compared between 2010 and 2020
Table 8.3: Number of Papers on MSCs by Source
Table 8.4: Number of Papers on Clinical Trials Involving MSCs, 2010-2020
Table 8.5: Number of Papers on Trials using MSCs for Specific Diseases, 2010-2020
Table 9.1: Number of Clinical Trials Involving MSCs by Region as of Apr. 2020
Table 9.2: Clinical Trials Involving MSCs by Source
Table 9.3: Clinical Trials Involving Autologous vs. Allogeneic MSCs
Table 9.4: Distribution of MSC-Based Clinical Trials by Geography, 2020
Table 9.5: Number of MSC-Based Clinical Trials by Country as of 2020
Table 9.6: Type of Funding for MSC-Based Clinical Trials, 2020
Table 9.7: The Three Types of Ongoing MSC-Based Clinical Trials, 2020
Table 9.8: MSC-Based Clinical Trials by Phase of Development, 2020
Table 9.9: Number of COVID-19 Clinical Trials by Country
Table 9.10: Examples of Clinical Trials involving MSC-Derived Exosomes
Table 9.11: NIH Funding for Research on MSCs, 2020
Table 9.12: CIRM-Funded MSC Projects
Table 9.13: MSC-Based Clinical Trials Funded by CIRM
Table 10.1: Examples of Bioengineered MSCs Loaded with Therapeutics
Table 10.2: Examples of Bioengineered MSCs used as Anti-Cancer Trojan Horses
Table 11.1: Select Cases of Modified MSC Applications and Therapeutic Outcome
Table 12.1: Select MSC-Based Clinical Trials for Autoimmune Diseases
Table 12.2: Select MSC-Based Clinical Trials for Cardiovascular Diseases
Table 12.3: Select MSC-Based Clinical Trials for Neurodegenerative Diseases
Table 12.4: Select MSC-Based Clinical Trials for Bone and Cartilage Diseases
Table 13.1: Examples of Completed Clinical Trials involving MSCs
Table 13.2: MSC Products with Marketing Approval
Table 13.3: Marketed Products Containing MSCs in Matrices
Table 13.4: Disease Conditions Studied using Stem Cell Conditioned Medium (CM)
Table 13.5: List of Stem Cell-Based Cosmetics
Table 14.1: Price Tags of MSC-Based Approved CT Products
Table 14.2: Price Tags for Select MSC Progenitor-Based Products
Table 14.3: Global Market for MSC-Based Cell Therapy by Geography, 2020-2027
Table 14.4: Global Market for Mesenchymal Stem Cells by Geography, 2020-2027
Table 15.1: Alexerion’s Exosome-Based Pipeline
Table 15.2: BrainStorm’s Product Pipeline
Table 15.3: Celltex Therapeutics’ Clinical Trials
Table 15.4: The Cellgram Pipeline from Pharmicell
Table 15.5: Pluristem’s Clinical Pipeline
Table 15.6: Sentien’s Pipeline
Table 15.7: Stemedica’s Clinical Pipeline

Note: Product cover images may vary from those shown
3 of 4
  • 101 Bio
  • Adipomics, Inc.
  • Aegle Therapeutics
  • Aethlon Medical, Inc.
  • AgeX Therapeutics, Inc.
  • Alexerion Biotech Corp.
  • AlloSource, Inc.
  • American CryoStem Corporation
  • American Type Culture Collection (ATCC)
  • AMS Biotechnology, Ltd. (AMSBIO)
  • Anemocyte S.r.l
  • Anjarium Biosciences
  • Anterogen, Co., Ltd.
  • Apceth Biopharma GmbH
  • Aruna Bio
  • Athersys, Inc.
  • Avalon GloboCare Corp.
  • Axol Bioscience, Ltd.
  • Azymus Therapeutics
  • Baylx, Inc.
  • BioEden
  • Bio-Techne
  • BioCat GmbH
  • BioFluidica
  • BioVision, Inc.
  • BrainStorm Cell Therapeutics
  • Capricor Therapeutics
  • Catalent Pharma Solutions
  • CCRM
  • CellResearch Corporation, Pte Ltd.
  • Celularity, Inc
  • Celltex Therapeutics Corporation
  • Ciloa
  • CO-DON AG
  • Codiak Biosciences
  • Cognate BioServices, Inc.
  • Corestem, Inc.
  • Creative Bioarray
  • Creative Biolabs
  • Cynata Therapeutics, Ltd.
  • DePuy Synthes
  • Direct Biologics
  • EVerZom
  • Evox Therapeutics, Ltd.
  • Exerkine Corp.
  • ExoCan Healthcare Technologies, Pvt. Ltd.
  • ExoCoBio, Co., Ltd.
  • Exogenus Therapeutics
  • EXoPERT
  • Exopharm
  • Exosome Diagnostics, Inc.
  • Exosome Sciences
  • ExosomePlus
  • Exosomics S.p.A
  • Fraunhofer Institute for Cell Therapy and Immunology
  • HansaBioMed Life Sciences, Ltd.
  • Hope Biosciences, LLC
  • Japan Tissue Engineering, Co., Ltd.
  • JCR Pharmaceuticals, Co., Ltd.
  • Kimera Labs, Inc.
  • Lonza Group Ltd.
  • Mantra Bio
  • MDimune
  • Medipost, Co., Ltd.
  • NanoSomix, Inc.
  • NanoView Biosciences
  • NeurExo Sciences
  • Nipro Corporation
  • Novus Biologicals, LLC
  • NuVasive, Inc.
  • OmniSpirant Limited
  • Orthocell, Ltd.
  • Orthofix Medical, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell, Co., Ltd.
  • Pluristem Therapeutics, Inc.
  • Regeneus, Ltd.
  • Regenexx
  • Regrow Biosciences, Pvt., Ltd.
  • ReNeuron
  • RoosterBio
  • RoslinCT
  • RTI Surgical, Inc.
  • Sentien Biotechnologies, Inc.
  • STEMCELL Technologies, Inc.
  • Stemedica Cell Technologies, Inc.
  • Stemmatters Biotechnologia e Medicina Regenerative SA
  • Stempeutics Research, Pvt., Ltd.
  • System Biosciences, LLC
  • Takeda Pharmaceuticals U.S.A., Inc.
  • Tavec Pharma
  • Tempo Bioscience
  • United Therapeutics Corp.
  • Vericel Corporation
  • Versatope Therapeutics
  • Vesigen Therapeutics, Inc.
  • Waisman Biomanufacturing
  • WuXi Advanced Therapies
  • XOStem, Inc.
  • Zen-Bio, Inc.
  • Zimmer Biomet
Note: Product cover images may vary from those shown
4 of 4

The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.

Input Sources

  • Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
  • Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
  • Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
  • Product Launch Announcements (Trade Journals, Google News)
  • Industry Events (Google News, Google Alerts, Press Releases)
  • Company News (SEC Filings, Investor Publications, Historical Performance)
  • Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
  • Interviews with Stem Cell Industry Leaders

Research & Analysis Methodologies

The publisher employs the following techniques for deriving its market research:

  • Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
  • Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
  • Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
  • Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
  • Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
  • Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
  • Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).
 

Loading
LOADING...

Adroll
adroll